UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2022

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

25 Recreation Park Drive, Unit 108
Hingham, Massachusetts 02043
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, Microbot Medical Inc. (the "Company") posted updated presentation materials on its website.

The presentation materials can be accessed via the 'Investors' section, under 'Presentation + Resources,' of the Company's website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials.

The presentation materials furnished as Exhibit 99.1 to this Current Report on Form 8-K are incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Presentation Materials
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: January 10, 2022

Exhibit 99.1


microbot
medical
ACCESS-ABILITY FOR ALL™
HAREL GADOT
Chief Executive Officer, President, and
Chairman of the Board of Directors

SAFE HARBOR STATEMENT

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, INC. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: risks inherent in the development and/or commercialization of potential products, including LIBERTY and the self-cleaning shunt; the outcome of our studies to evaluate LIBERTY and the SCS and other existing and future technologies; uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals; uncertainty resulting from the COVID-19 pandemic; need and ability to obtain future capital; maintenance of intellectual property rights; our ability to find and develop applications for our technologies for other neurosurgical conditions besides hydrocephalus; our clinical development and other research and development plans and expectations; the safety and efficacy of our product candidates; the anticipated regulatory pathways for our product candidates; our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all; the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory agencies; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.


SURGICAL ROBOTICS: MARKET OPPORTUNITY
U.S. Market for Surgical Robotics
19 Million
Procedures in 2019
>5% used a Robotic Device
~95%
of Addressable Market Remains Available
+15-20%
Market Growth in Endoluminal Robotic Surgery by 2025 (est.)

TOTAL ADDRESSABLE US MARKET: ENDO-VASCULAR

>5M PROCEDURES[1]

Across Coronary, Peripheral and Neuro



WHY LOW PENETRATION?

- Capital expense
- Cumbersome and expensive disposables
- Extended set-up time
- Large footprint
- Dedicated infrastructure
- Special training, long learning curve

<1% DONE ROBOTICALLY[2]

1 Medtech 360 Reports
2 Deduced from Public Records

ELIMINATING BARRIERS, ALLOWING ACCESS

Disposable
No capital expense
Increases procedure efficiency

Small Footprint
No dedicated infrastructure required

Remote
Reduce exposure to radiation and HAIs
Allows access in remote facilities

Mobile
Can be utilized in multiple sites of service

Universal
Any off-the-shelf instrument

2021 MILESTONES

Strategic Collaboration

Design Freeze

Achieved Design Freeze for the LIBERTY Robotic System, paving the way for the Company to build momentum heading into 2022 and the future pre-clinical and clinical trials.

Feasability Studies

Announced the results of a second feasibility animal study using the LIBERTY Robotic System, navigating to a clot, crossing the clot, deploying a stent retriever, and manually retrieving an arterial clot in a live pig. All the end points were met with no intraoperative adverse events. This study, along with others performed afterwards were invaluable and allowed the Company to refine the system as it progressed towards a Design Freeze.

IP Portfolio Growth

Strengthened its IP Portfolio with Global Patent Allowances, including the One & Done Guidewire Technology, resulting in a total of 46 patents issued/ allowed and 24 pending patent applications

EFS Designation

Successfully concluded discussions with the U.S. Food and Drug Administration (FDA) for Self-Cleaning Shunt (SCS), allowing the Company to apply for a limited clinical investigation known as an Early Feasibility Study (EFS), which is designed for novel technologies such as the SCS.

Operational Efficiency

Strengthened its management team with key personnel to build market awareness in the U.S. and enhanced its Scientific Advisory Board with leading medical device expertise.

Maintained a solid balance sheet: managing expenses, no debt and the resources to execute its 2022 objectives related to LIBERTY®


stryker

UNDERSERVED MARKET: NEURO-VASCULAR

1M
Stroke Incidences

40K
Treated

NEURO

ISCHEMIC STROKE

- >400% total growth in Patients Treated over the past 7 years[1]
- Leading Cause of long-term disability costing healthcare $184B in 2020[2]



WHY ARE SO FEW TREATED?

LACK OF ACCESS TO:

- Experts • Comprehensive Stroke Centers
- Skilled personnel • Neuro Specific Technology

[1] O. Ben-Joseph and S. Benussen, "Stroke Devices: Neurovascular Device Market Poised for Growth" MedTech Strategist May 29, 2018. Vol. 5, No. 7 pg 24
[2] IBID Pg 20

MOVING FROM A PRODUCT-BASED SOLUTION…

stryker

microbot medical



TO WORLD'S FIRST DEDICATED ROBOTIC PROCEDURAL KIT

stryker microbot medical

Disposable Kit
Efficient total procedure time

Remote Access
Delivering best-in-class treatment to everyone everywhere

Democratization
Eliminating procedural variability




2022 GOALS
stryker
Continuous collaboration for dedicated neurovascular kits
Pre-Submission
Finalize U.S. Food and Drug Administration (FDA) pre-submission for the LIBERTY Robotic System by the end of Q1 2022
Collaboration
Continue to explore M&A and strategic collaboration opportunities to enhance the Company's assets and core capabilities
Commercialization Readiness
Establish a strong network of centers of excellence in US, Europe and Israel in anticipation of commercial launch in 2023
Key Opinion Leaders
Continue to engage with Key Opinion Leaders (KOLs) and leading academic centers to educate and raise awareness of the LIBERTY Robotic System
Trials
Initiate pre-clinical trial for LIBERTY Robotic System in Q2 /Q3 of 2022
Pending FDA feedback, clinical trial process to commence in Q4 2022
Continue EFS readiness for SCS
IP Portfolio
Expand and protect the Company's global IP portfolio in global jurisdictions, which creates significant barriers to entry
Pipeline Development
Continue developing LIBERTY® ecosystem to include instruments (one-and-done), big data, etc